60 Degrees announces detection of babesia infection in 24% of patients in study

60 Degrees Pharmaceuticals (SXTP) announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens. Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that Babesia and chronic disease may be linked – specifically, that Babesia infection may prolong recovery times in patients with chronic fatigue. The results also reinforce the importance of the B-Free Chronic Babesiosis Study, which is evaluating efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days for resolution of severe fatigue in patients with chronic babesiosis. The Company’s B-Free Study is now enrolling at the Icahn School of Medicine at Mount Sinai in New York. “Healthcare providers who treat tick-borne illness may not be surprised by the results of this study,” said CEO Geoffrey Dow. “While the results don’t prove that Babesia infection causes chronic disease, they are consistent with that hypothesis and highlight the need for prospective controlled studies which the Company is now undertaking.”